A Phase 1 interventional study of AB001 and oral capsule in Chronic Low Back Pain, sponsored by Frontier Biotechnologies Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-30.
Sponsored by Frontier Biotechnologies Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Low Back Pain with a site in China — 17 open to participants now, 19 under way, none of them phase 3. Low Back Pain · China.
Among the 49 studies in Low Back Pain with a site in China, this one is the 36th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 1, and was the 13th registered.
2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.
Browse Low Back Pain studies →17 of the 49 studies in Low Back Pain with a site in China are open now. Recruiting first, the newest first:
Chinese PLA General Hospital · Sites in China
Ages 18–80
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Universiti Sains Malaysia · Sites in China
Ages 20–55
Xijing Hospital · Sites in China
Ages 18–65
Xijing Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 332 Low Back Pain studies recruiting now, 92 (28%) set no upper age limit and 210 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 2 · Phase 4 2
First in 2008; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 60 across 2,364 interventional studies indexed under Low Back Pain.
Median enrollment 84 across the 42 interventional studies, 300 across the 7 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 49 have an industry lead sponsor. The 10 most frequent:
Frontier Biotechnologies Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Frontier Biotechnologies Inc. has 2 studies filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
2 of the studies in Low Back Pain with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07892846Chinese PLA General HospitalThe Intervention Effect of Exercise on Lumbar Multifidus Muscle Injuries | 2027-05 |
| NCT07858188Nanfang Hospital, Southern Medical UniversityStudy on the Effect of Electronic Moxibustion on Non-Specific Low Back Pain in Young Adults | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 49 studies in Low Back Pain with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study evaluates the safety, tolerability and pharmacokinetics of single and repeated doses of topical AB001 patch and the bioavailability relative to the oral capsule and topical positive comparative patch.
Eligible subjects will be randomly assigned to Treatment goup A, B and C.
In the experiment group A, 12 subjects with a ratio of 10:2 will receive one patch of AB001 or placebo batch on Day 1 of period 1, respectively, after a wash-out period of 14 days, 10 subjects received AB001 patch will be administered with an oral capsule of active ingredient on Day 20 of period 2.
In the experiment group B, 12 subjects with a ratio of 10:2 will receive two patches of AB001 or two placebo batches on Day 1 respectively, and then two patches daily from Day 8 to Day 20.
In the active comparator group C, 10 subjects will receive one patch of positive comparative patch on Day 1, and then once patch every two days from Day 8 to Day 20.
The tolerability, safety and pharmacokinetics of topical AB001 patch will be assessed in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apply 1 patch of AB001 patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1. Subjects who received the AB001 patch in period 1 will then receive a single oral capsule of active ingredient on Day 20 in period 2.
Drug: AB001 · Drug: oral capsule
Apply 2 patches of AB001 patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
Drug: AB001
Apply 1 patch of positive comparative patch on the lower back of the subjects on either side of the spine without occlusion for 48 hours on Day 1 and then one patch every two days from Days 8 to 20.
Drug: positive comparative patch
Apply 1 patch of placebo patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1.
Drug: Placebos
Apply 2 patches of placebo patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
Drug: Placebos
single and repeated dosing
Also known as: topical patch
single dose
Also known as: active ingredient
single and repeated dosing
Also known as: topical patch
single and repeated dosing
Also known as: topical patch
Number of subjects with any adverse events (AEs)
An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: From baseline through Day 26
Number of subjects any serious adverse events (SAEs)
An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect.
Time frame: From baseline through Day 26
Safety Assessments on Skin Reaction Evaluation
Topical Skin Reaction Score(0-2 is a better outcome): 0= no evidence of irritation 1. minimal erythema, barely perceptible 2. definite erythema, readily visible; minimal edema or minimal papular response 3. erythema and papules 4. definite edema 5. erythema, edema and papules 6. vesicular eruption 7. strong reaction spreading beyond application site
Time frame: From baseline through Day 26
pharmacokinetic parameters of AB001(Cmax)
Peak Plasma Concentration (Cmax)
Time frame: Day 1 and Day 26
pharmacokinetic parameters of AB001 (AUC)
Area under the plasma concentration versus time curve (AUC)
Time frame: Day 1 and Day 26
bioavailability of AB001
To determine the bioavailability of AB001
Time frame: Day 1 and Day 26
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2019 to primary completion in Nov 2019, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AB-001
Frontier Biotechnologies Inc.